Mumbai, India, June 24, 2019: GlenmarkPharmaceuticals Ltd (Glenmark), a research-led globalintegrated pharmaceutical company, today announced thatits Brazilian subsidiary, Glenmark Farmacêutica Ltdahas entered into an exclusive partnershipagreement with Novartis Biosciences S.A, a subsidiary of NovartisAG, for three respiratory productsindicatedtowards treatment of the symptoms of chronic obstructive pulmonary disease (COPD)in Brazil.This agreement will be effective from July 01, 2019 onwards.

Continue reading

Novartis has announced that a phase III QUARTZ study of its investigational inhaled combination treatment, QMF149, has met primary and key secondary endpoints in patients with inadequately controlled asthma. The once-daily, fixed-dose treatment demonstrated significant improvements in lung function and asthma control versus inhaled corticosteroid (ICS) alone.

Continue reading

  • 1
  • 2
  • 5
logo

Logistic 3PL
Center Biokon

We are in social networks

9.00 to 18.00
+38 (044) 585-11-80
+38 (044) 585-11-81
trade[at]biocon-bc.com
9 Boryspilska St., Velyka Olexandrovka Village, Boryspilskyi District, 08320, Kyiv Region

© 2018 «BIOKON» All rights reserved.